Research programme: AAV ocular gene therapy - Novartis/Vedere Bio
Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Vedere Bio
- Developer Novartis; Vedere Bio
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders